JK1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
CML · Chronic Myelogenous Leukemia
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- CML
- cancer_type_detailed
- Chronic Myelogenous Leukemia
- subtype
- —
- cancer_type
- CML
- ccle_sample_id
- JK1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
- synthetic_from_ccle
- true
- display_name
- JK-1
- ccle_lineage
- blood
- ccle_lineage_subtype
- CML
- ccle_lineage_sub_subtype
- blast_crisis
- oncotree_code
- CML
- cancer_type_detailed
- Chronic Myelogenous Leukemia
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEME_METABOLISM+3.271
- INTERFERON_ALPHA_RESPONSE+0.239
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.232
- ALLOGRAFT_REJECTION+0.138
- COMPLEMENT+0.076
- IL6_JAK_STAT3_SIGNALING+0.061
- P53_PATHWAY+0.032
- INTERFERON_GAMMA_RESPONSE+0.012
- SPERMATOGENESIS-0.001
- INFLAMMATORY_RESPONSE-0.005
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.656
- NOTCH_SIGNALING-0.593
- E2F_TARGETS-0.551
- GLYCOLYSIS-0.550
- UV_RESPONSE_DN-0.494
- MITOTIC_SPINDLE-0.489
- TGF_BETA_SIGNALING-0.448
- MYC_TARGETS_V2-0.446
- ESTROGEN_RESPONSE_LATE-0.408
- APICAL_JUNCTION-0.406
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | F36P_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.895 |
| 2 | OCIM1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.747 |
| 3 | NCO2_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | CML | — | 0.738 |
| 4 | KU812_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | CML | — | 0.717 |
| 5 | CMK_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.711 |
| 6 | LAMA84_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | CML | — | 0.680 |
| 7 | HEL_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.680 |
| 8 | KYO1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | CML | — | 0.670 |
| 9 | MEG01_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | CML | — | 0.655 |
| 10 | MOLM16_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.654 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEME_METABOLISM | 3.271 | Temsirolimus | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.239 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.232 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.138 | Idelalisib | — uncovered |
| COMPLEMENT | 0.076 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.061 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.032 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.012 | Idelalisib | — uncovered |